{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:01:57Z","timestamp":1785859317235,"version":"3.56.0"},"reference-count":30,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019271","name":"Kyorin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019271","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["LUTS"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>This study aimed to evaluate the efficacy and safety of Vibegron for the treatment of residual overactive bladder (OAB) symptoms after laser vaporization of the prostate (photo\u2010selective vaporization of the prostate, contact laser vaporization of the prostate, and thulium laser vaporization).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This randomized, open\u2010label, parallel\u2010group, single\u2010center superiority trial with a 12\u2010week observation (jRCTs071190040) enrolled male patients with OAB aged 40\u2009years or older who had undergone laser vaporization of the prostate for not less than 12\u2009weeks and not more than 1\u2009year earlier. Patients were allocated to receive Vibegron 50\u2009mg once daily or follow\u2010up without treatment for 12\u2009weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Forty\u2010seven patients were enrolled between January 2020 and March 2023. The median age (interquartile range) was 75.5 (72.5\u201378.5) years for the Vibegron group and 76.5 (71.0\u201381.0) years for the control group. The intergroup difference in the mean change (95% confidence interval) in the 24\u2010hour urinary frequency at 12\u2009weeks after randomization was \u22123.66 (\u22124.99, \u22122.33), with a significant decrease for the Vibegron group. The Overactive Bladder Symptom Score, International Prostate Symptom Score, IPSS storage score, and Overactive Bladder Questionnaire score significantly improved for the Vibegron group. Voided volume per micturition also increased for the Vibegron group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The administration of 50\u2009mg of Vibegron once daily for 12\u2009weeks showed significant improvement compared with follow\u2010up without treatment in bladder storage (OAB) symptoms after laser vaporization of the prostate for symptomatic benign prostatic hyperplasia.<\/jats:p><\/jats:sec>","DOI":"10.1111\/luts.12529","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T06:05:53Z","timestamp":1719986753000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of Vibegron for the treatment of residual overactive bladder symptoms after laser vaporization of the prostate: A single\u2010center prospective randomized controlled trial (<scp>VAPOR TRIAL<\/scp>)"],"prefix":"10.1111","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5178-4237","authenticated-orcid":false,"given":"Narihito","family":"Seki","sequence":"first","affiliation":[{"name":"Department of Urology Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Masaoka","sequence":"additional","affiliation":[{"name":"Department of Urology Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoohyun","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Urology Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1702-0000","authenticated-orcid":false,"given":"Takashi","family":"Dejima","sequence":"additional","affiliation":[{"name":"Department of Urology Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Urology Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0750-2172","authenticated-orcid":false,"given":"Shotaro","family":"Maeda","sequence":"additional","affiliation":[{"name":"Medical Affairs Kyorin Pharmaceutical Co, Ltd  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)66256-6"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)67059-9"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-008-9333-z"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(94)80197-5"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)32831-8"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2010.02687.x"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2009.02333.x"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.07.001"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1089\/end.2007.0137"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2007.09.017"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12324"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12453"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-018-0847-3"},{"key":"e_1_2_11_15_1","volume-title":"The Japanese Urological Association. Clinical Guideline of Benign Prostatic Hyperplasia","year":"2017"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003698"},{"key":"e_1_2_11_17_1","unstructured":"EAU Guidelines. Presented at the EAU Annual Congress Milan March 2023. ISBN 978\u201094\u201092671\u201019\u20106."},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756287217742837"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.12.022"},{"key":"e_1_2_11_20_1","unstructured":"U.S. Food and Drug Administration.Drug approval package: Gemtesa.2020. Accessed February 6 2024.https:\/\/www.fda.gov\/media\/147397\/download"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1188619"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-005-4031-6"},{"key":"e_1_2_11_23_1","first-page":"2684","article-title":"Lower urinary tract symptoms and efficacy of anticholinergic drugs in patients remaining disease\u2010free after radical retropubic prostatectomy","volume":"13","author":"Yang SW","year":"2016","journal-title":"Urol J"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2006.02.042"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2011.06.020"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2006.03.088"},{"key":"e_1_2_11_27_1","unstructured":"Ministry of Health Labor and Welfare (MHLW).Clinical Trials Act. Accessed February 6 2024.https:\/\/www.mhlw.go.jp\/file\/06-Seisakujouhou-10800000-Iseikyoku\/0000213334.pdf"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1308\/rcsann.2010.92.7.555"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2019.06.020"},{"key":"e_1_2_11_30_1","first-page":"89","article-title":"Tehnic\u0103 inovatoare in tratamentul endoscopic al adenomului de prostat\u0103 voluminos\u2013enucleerea prin vaporizare cu plasm\u0103 [Innovative technique in large benign prostatic hyperplasia\u2013enucleation by plasma vaporization]","volume":"107","author":"Geavlete B","year":"2012","journal-title":"Chirurgia"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-44686-2"}],"container-title":["LUTS: Lower Urinary Tract Symptoms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/luts.12529","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:35:08Z","timestamp":1722386108000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/luts.12529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1111\/luts.12529"],"URL":"https:\/\/doi.org\/10.1111\/luts.12529","archive":["Portico"],"relation":{},"ISSN":["1757-5664","1757-5672"],"issn-type":[{"value":"1757-5664","type":"print"},{"value":"1757-5672","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"2024-02-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e12529"}}